ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
ImmuCell Corporation (NASDAQ: ICCC) has announced it will release its unaudited financial results for Q1 2025 after market close on May 14, 2025. The company will host a conference call on May 15, 2025, at 9:00 AM ET to discuss the results. The company maintains its preliminary sales results disclosed on April 8, 2025, with no anticipated changes. The Q1 2025 Form 10-Q filing is expected on May 14, 2025.
ImmuCell, focused on dairy and beef cattle health products, manufactures First Defense® for newborn calf immunity and is developing Re-Tain® for subclinical mastitis treatment in dairy cows. An updated Corporate Presentation will be available on the company's website after market close on May 14.
ImmuCell Corporation (NASDAQ: ICCC) ha annunciato che pubblicherà i risultati finanziari non revisionati del primo trimestre 2025 dopo la chiusura del mercato il 14 maggio 2025. L'azienda terrà una conference call il 15 maggio 2025 alle 9:00 AM ET per discutere i risultati. La società conferma i risultati preliminari delle vendite comunicati l'8 aprile 2025, senza prevedere modifiche. La presentazione del modulo 10-Q per il primo trimestre 2025 è prevista per il 14 maggio 2025.
ImmuCell, specializzata in prodotti per la salute del bestiame da latte e da carne, produce First Defense® per l'immunità dei vitelli neonati e sta sviluppando Re-Tain® per il trattamento della mastite subclinica nelle vacche da latte. Una versione aggiornata della Presentazione Aziendale sarà disponibile sul sito web della società dopo la chiusura del mercato il 14 maggio.
ImmuCell Corporation (NASDAQ: ICCC) ha anunciado que publicará sus resultados financieros no auditados del primer trimestre de 2025 después del cierre del mercado el 14 de mayo de 2025. La empresa realizará una conferencia telefónica el 15 de mayo de 2025 a las 9:00 AM ET para analizar los resultados. La compañía mantiene los resultados preliminares de ventas divulgados el 8 de abril de 2025, sin cambios previstos. Se espera que la presentación del Formulario 10-Q del primer trimestre de 2025 se realice el 14 de mayo de 2025.
ImmuCell, enfocada en productos para la salud del ganado lechero y de carne, fabrica First Defense® para la inmunidad de terneros recién nacidos y está desarrollando Re-Tain® para el tratamiento de la mastitis subclínica en vacas lecheras. Una Presentación Corporativa actualizada estará disponible en el sitio web de la compañía después del cierre del mercado el 14 de mayo.
ImmuCell Corporation (NASDAQ: ICCC)는 2025년 1분기 감사 전 재무 결과를 2025년 5월 14일 장 마감 후 발표할 예정입니다. 회사는 2025년 5월 15일 오전 9시(동부시간)에 실적 관련 컨퍼런스 콜을 진행할 예정입니다. 2025년 4월 8일에 공개한 예비 매출 결과를 변경 없이 유지한다고 밝혔습니다. 2025년 1분기 Form 10-Q 제출은 5월 14일로 예정되어 있습니다.
ImmuCell은 낙농 및 육우 건강 제품에 주력하며, 신생 송아지 면역을 위한 First Defense®를 제조하고 있으며, 낙농우의 잠복성 유선염 치료를 위한 Re-Tain® 개발 중입니다. 최신 기업 프레젠테이션은 5월 14일 장 마감 후 회사 웹사이트에서 확인할 수 있습니다.
ImmuCell Corporation (NASDAQ: ICCC) a annoncé qu'elle publiera ses résultats financiers non audités du premier trimestre 2025 après la clôture du marché le 14 mai 2025. La société tiendra une conférence téléphonique le 15 mai 2025 à 9h00 ET pour discuter des résultats. Elle confirme les résultats préliminaires des ventes divulgués le 8 avril 2025, sans changement prévu. Le dépôt du formulaire 10-Q pour le premier trimestre 2025 est attendu le 14 mai 2025.
ImmuCell, spécialisée dans les produits pour la santé du bétail laitier et bovin, fabrique First Defense® pour l'immunité des veaux nouveau-nés et développe Re-Tain® pour le traitement de la mammite subclinique chez les vaches laitières. Une présentation d'entreprise mise à jour sera disponible sur le site internet de la société après la clôture du marché le 14 mai.
ImmuCell Corporation (NASDAQ: ICCC) hat angekündigt, die ungeprüften Finanzergebnisse für das erste Quartal 2025 nach Börsenschluss am 14. Mai 2025 zu veröffentlichen. Das Unternehmen wird am 15. Mai 2025 um 9:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Die vorläufigen Umsatzergebnisse, die am 8. April 2025 bekannt gegeben wurden, bleiben unverändert. Die Einreichung des Formulars 10-Q für das erste Quartal 2025 wird am 14. Mai 2025 erwartet.
ImmuCell, spezialisiert auf Gesundheitsprodukte für Milch- und Rindfleischvieh, stellt First Defense® für die Immunität neugeborener Kälber her und entwickelt Re-Tain® zur Behandlung subklinischer Mastitis bei Milchkühen. Eine aktualisierte Unternehmenspräsentation wird nach Börsenschluss am 14. Mai auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ET
PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025.
The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until May 22, 2025 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #4755970.
The Company anticipates no change to the preliminary sales results for the first quarter ended March 31, 2025 that were disclosed on April 8, 2025. The Company expects to file its Quarterly Report on Form 10-Q on May 14, 2025 after the market closes.
Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company. An updated version of the slide deck will be made available after the market closes on Wednesday, May 14, 2025.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional mastitis antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Michael F. Brigham, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| (207) 878-2770 | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| (602) 889-9700 | |
| iccc@lythampartners.com |
FAQ
When will ImmuCell (ICCC) report its Q1 2025 financial results?
How can investors join ImmuCell's Q1 2025 earnings conference call?
What are ImmuCell's (ICCC) main products?
Where can investors access ImmuCell's corporate presentation?
